RxDoctor Payments DataLook up a doctor →

Anita Kohli, MD

Infectious Disease · Chandler, AZNPI 1619189800

Payments from drug & device makers

$24,271,170in general payments, 2019–2025

Across 3,318 payments — averaging $7315.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$5.2M
  • Modernatx, Inc.$5.1M
  • Intercept Pharmaceuticals, Inc.$3.3M
  • Madrigal Pharmaceuticals$2.3M
  • Gilead$1.8M
  • Eli Lilly$928K
  • plus $5.5M from 43 others
$173,130in research payments, 2019–2025

Across 12 payments — averaging $14,427 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$151K
  • Bausch Health US, LLC$21K
  • Regeneron$1K
  • Gilead$67

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$24,271,170 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.

See all infectious disease providers in Arizona

Medicare billing

Part B allowed, 2024
$122,404
Medicare patients
430
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →